Advertisement

Lipoprotein-associated phospholipase A2 (Lp-PLA2) and risk of cardiovascular disease in older adults: Results from the Cardiovascular Health Study

      Abstract

      Objective

      To examine associations between lipoprotein-associated phospholipase A2 (Lp-PLA2) antigen level (mass) and enzymatic activity (activity) and cardiovascular disease (CVD) in older adults.

      Methods

      We examined associations of Lp-PLA2 mass and activity with incident myocardial infarction (MI; n = 508), stroke (n = 565) and CVD death (n = 665) using Cox regressions adjusted for age, sex, ethnicity and CVD risk factors in 3949 older adults, aged ≥65 years at baseline, from the Cardiovascular Health Study (CHS).

      Results

      Lp-PLA2 was associated with incident CVD events in these older adults. Hazard ratios (95% confidence intervals) for highest versus lowest tertiles of Lp-PLA2 mass were 1.49 (1.19–1.85) for MI, 1.21 (0.98–1.49) for stroke and 1.11 (0.92–1.33) for CVD death. The highest tertile of Lp-PLA2 activity was associated with MI (1.36; 1.09–1.70) and CVD death (1.23; 1.02–1.50). Combined Lp-PLA2 tertile 3 and CRP > 3 mg/l, compared to Lp-PLA2 tertile 1 and CRP < 1 mg/l, was associated with MI (2.29; 1.49–3.52) for Lp-PLA2 mass and MI (1.66; 1.10–2.51) and CVD death (1.57; 1.08–2.26) for activity. For MI, both mass and activity added excess risk to elevated CRP alone (∼20% excess risk) and activity added excess risk for CVD death (∼12%).

      Conclusion

      Lp-PLA2 mass and activity were associated with incident CVD events in older adults in CHS. Lp-PLA2 and CRP were independent and additive in prediction of events. While associations were modest, these results support further exploration of Lp-PLA2 to identify older individuals at risk for CVD.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Zalewski A.
        • Macphee C.
        Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target.
        Arterioscler Thromb Vasc Biol. 2005; 25: 923-931
        • Kolodgie F.D.
        • Burke A.P.
        • Skorija K.S.
        • et al.
        Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis.
        Arterioscler Thromb Vasc Biol. 2006; 26: 2523-2529
        • Oei H.H.
        • van der Meer I.M.
        • Hofman A.
        • et al.
        Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam study.
        Circulation. 2005; 111: 570-575
        • van Vark L.C.
        • Kardys I.
        • Bleumink G.S.
        • et al.
        Lipoprotein-associated phospholipase A2 activity and risk of heart failure: the Rotterdam study.
        Eur Heart J. 2006; 27: 2346-2352
        • Packard C.J.
        • O’Reilly D.S.
        • Caslake M.J.
        • et al.
        Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease.
        N Engl J Med. 2000; 343: 1148-1155
        • Koenig W.
        • Khuseyinova N.
        • Lowel H.
        • Trischler G.
        • Meisinger C.
        Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.
        Circulation. 2004; 110: 1903-1908
        • Ballantyne C.M.
        • Hoogeveen R.C.
        • Bang H.
        • et al.
        Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
        Circulation. 2004; 109: 837-842
        • Blake G.J.
        • Dada N.
        • Fox J.C.
        • Manson J.E.
        • Ridker P.M.
        A prospective evaluation of lipoprotein-associated phospholipase A (2) levels and the risk of future cardiovascular events in women.
        J Am Coll Cardiol. 2001; 38: 1302-1306
        • Persson M.
        • Nilsson J.A.
        • Nelson J.J.
        • Hedblad B.
        • Berglund G.
        The epidemiology of Lp-PLA (2): distribution and correlation with cardiovascular risk factors in a population-based cohort.
        Atherosclerosis. 2007; 190: 388-396
        • Burke A.P.
        • Farb A.
        • Pestaner J.
        • et al.
        Traditional risk factors and the incidence of sudden coronary death with and without coronary thrombosis in blacks.
        Circulation. 2002; 105: 419-424
        • Fried L.P.
        • Borhani N.O.
        • Enright P.
        • et al.
        The Cardiovascular Health Study: design and rationale.
        Ann Epidemiol. 1991; 1: 263-276
        • Cushman M.
        • Cornell E.S.
        • Howard P.R.
        • Bovill E.G.
        • Tracy R.P.
        Laboratory methods and quality assurance in the Cardiovascular Health Study.
        Clin Chem. 1995; 41: 264-270
        • Macy E.M.
        • Hayes T.E.
        • Tracy R.P.
        Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications.
        Clin Chem. 1997; 43: 52-58
        • Kardys I.
        • Oei H.H.
        • van der Meer I.M.
        • Hofman A.
        • Breteler M.M.
        • Witteman J.C.
        Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam study.
        Arterioscler Thromb Vasc Biol. 2006; 26: 631-636
        • Rothman K.J.
        Modern epidemiology.
        Little, Brown, and Company, Boston/Toronto1986 (pp. 317–25)
        • Hosmer D.W.
        • Lemeshow S.
        Confidence interval estimation of interaction.
        Epidemiology. 1992; 3: 452-456
        • Daniels L.B.
        • Laughlin G.A.
        • Sarno M.J.
        • Bettencourt R.
        • Wolfert R.L.
        • Barrett-Connor E.
        Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study.
        J Am Coll Cardiol. 2008; 51: 913-919
        • Ballantyne C.M.
        • Hoogeveen R.C.
        • Bang H.
        • et al.
        Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
        Arch Intern Med. 2005; 165: 2479-2484
        • Jenny N.S.
        • Yanez N.D.
        • Psaty B.M.
        • Kuller L.H.
        • Hirsch C.H.
        • Tracy R.P.
        Inflammation biomarkers and near-term death in older men.
        Am J Epidemiol. 2007; 165: 684-695
        • Stamler J.
        • Daviglus M.L.
        • Garside D.B.
        • Dyer A.R.
        • Greenland P.
        • Neaton J.D.
        Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity.
        JAMA. 2000; 284: 311-318
        • Psaty B.M.
        • Anderson M.S.
        • Kronmal R.A.
        • et al.
        The association between lipid levels and the risks of incident myocardial infarction, stroke and total mortality: the Cardiovascular Health Study.
        J Am Geriatr Soc. 2004; 52: 1639-1647
        • Ballantyne C.
        • Cushman M.
        • Psaty B.
        • et al.
        Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases.
        Eur J Cardiovasc Prev Rehabil. 2007; 14: 3-11
        • Wolfert R.L.
        • Kim N.W.
        • Selby R.G.
        • Sarno M.J.
        • WarnicK R.G.
        • Sudhir K.
        Biological variability and specificity of lipoprotein-associated phospholipase A2 (Lp-PLA2), a novel marker of cardiovascular risk.
        Circulation. 2004; 110: 309